Publication | Closed Access

A Phase II Study of the MDR Inhibitor Biricodar (INCEL, VX-710) and Paclitaxel in Women with Advanced Ovarian Cancer Refractory to Paclitaxel Therapy

Mdr Inhibitor BiricodarMedicineMetronomic TherapyGynecologyPhase Ii StudyPharmacotherapyCancer TreatmentOncologyRadiation OncologyPaclitaxel TherapyGynecology OncologyOvarian Cancer